Raymond James Financial
HBIO icon

Raymond James Financial’s Harvard Bioscience HBIO Stock Holding History

Raymond James Financial’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-375
Closed -$1.66K – 5721
2025
Q2 		$1.66K Buy
+375
New +$1.57K ﹤0.01% 6450

Other funds holding HBIO

AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James Financial's HBIO Position: Q3 2025 in Review

Raymond James Financial sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 375 shares — an estimated $1.66K sold.

Raymond James Financial first reported a position in HBIO in Q2 2025 and held it in 1 quarter. The position peaked at $1.66K in Q2 2025. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

  • Raymond James Financial reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 375 Harvard Bioscience shares in Q3 2025, an estimated $1.66K.
  • Raymond James Financial first reported a position in Harvard Bioscience in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Harvard Bioscience position peaked at $1.66K in Q2 2025.
  • 59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.